I consider using second-generation SSAs for any symptomatic patient with above normal IGF-1(≥1.5-2ULN) with unresectable residual tumor that does not respond to the maximum tolerated dose of SSA (usually 40 mg octreotide or 120 mg lanerotide monthly) for at least 6 months. Here, IGF1 is linked to neoplasm.